Breckenridge Pharmaceutical Initiates Nationwide Recall of Duloxetine Due to Nitrosamine Impurity and CGMP Deviations
Breckenridge Pharmaceutical, Inc. has initiated a U.S. nationwide Class II recall of Duloxetine Delayed-Release Capsules, 40mg, due to N-nitroso-duloxetine impurity exceeding FDA interim limits and associated CGMP deviations. This event, impacting 12,242 bottles, underscores critical quality control failures at the manufacturing site, Towa Pharmaceutical Europe, S.L., necessitating immediate action for procurement and regulatory teams.
FDA-Mandated Recall of Breckenridge Duloxetine: Impurity and CGMP Violations Identified
Breckenridge Pharmaceutical, Inc. has initiated a voluntary, firm-initiated Class II recall across the U.S. for specific lots of Duloxetine Delayed-Release Capsules, USP, 40mg. This significant regulatory action, designated recall number D-0511-2025, stems from identified Current Good Manufacturing Practice (CGMP) deviations and the presence of N-nitroso-duloxetine impurity above the FDA's recommended interim limits. The recall, initiated on June 30, 2025, and reported to the FDA on July 16, 2025, impacts 12,242 30-count bottles of the antidepressant, specifically Lot # 230199 with an expiration date of January 31, 2026 (NDC 51991-750-33). For procurement directors, this event necessitates an immediate review of all Duloxetine Hydrochloride supply contracts, particularly those involving Breckenridge Pharmaceutical, Inc., to ascertain exposure to affected or potentially compromised batches. Regulatory affairs heads must assess the implications of these CGMP deviations, especially concerning nitrosamine impurities, which remain a high-priority focus for global health authorities. The presence of such impurities signals a critical breakdown in quality control and manufacturing process validation at the production facility, Towa Pharmaceutical Europe, S.L., located in Martorelles, Spain, which manufactured the recalled product.
Manufacturing Site Under Scrutiny: Towa Pharmaceutical Europe's Role in Duloxetine Production
The manufacturing site implicated in the Duloxetine recall is Towa Pharmaceutical Europe, S.L., situated in Martorelles, Barcelona, Spain. While Breckenridge Pharmaceutical, Inc. (based in Berkeley Heights, NJ) acts as the distributor for the U.S. market, the root cause of the CGMP deviations and the N-nitroso-duloxetine impurity originates from the manufacturing processes at the Spanish facility. This highlights a critical vulnerability for business development executives and supply chain VPs who rely on third-party manufacturers. The incident underscores the imperative for rigorous due diligence and continuous oversight of contract manufacturing organizations (CMOs), regardless of their geographic location. Any company sourcing active pharmaceutical ingredients (APIs) or finished drug products from Towa Pharmaceutical Europe, S.L. should immediately initiate a comprehensive quality audit and risk assessment. The FDA's Class II classification indicates that the impurity could cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This classification, however, does not diminish the commercial and reputational risk associated with such a manufacturing lapse. Procurement teams must understand the full scope of products manufactured at this facility to proactively identify and mitigate potential future supply chain disruptions.
Supply Chain Exposure: Nationwide Impact for Duloxetine Hydrochloride
The recall of Duloxetine Delayed-Release Capsules, USP, 40mg, distributed by Breckenridge Pharmaceutical, Inc., has a U.S. nationwide distribution pattern, directly impacting pharmacies, wholesalers, and ultimately, patients across the country. Duloxetine Hydrochloride, a widely prescribed serotonin-norepinephrine reuptake inhibitor (SNRI), is critical for treating major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. The withdrawal of 12,242 30-count bottles from the market, under ANDA203088, while not a catastrophic volume for the entire U.S. market, represents a significant disruption for specific supply channels and healthcare providers reliant on Breckenridge's product. Supply chain VPs must assess their current inventory levels of Duloxetine from all suppliers and evaluate potential shortfalls. This event serves as a stark reminder for procurement directors to diversify their sourcing strategies for essential generic medications. Over-reliance on a single distributor or manufacturer, even for a generic product with multiple ANDAs, can expose businesses to significant operational and reputational risks when quality issues emerge. The market for Duloxetine, while competitive, can experience localized shortages or price fluctuations due to such recalls, affecting patient access and increasing procurement costs.
Navigating Alternative Suppliers Amidst Limited Public Information
For procurement directors and supply chain VPs, identifying and qualifying alternative suppliers for Duloxetine Hydrochloride is paramount following this recall. While the ChemLifeIntel Knowledge Graph does not explicitly name alternative suppliers for Duloxetine, the generic nature of Duloxetine Hydrochloride (ANDA203088) implies that multiple manufacturers hold FDA approvals. This situation necessitates a proactive market scan to identify other approved ANDA holders for Duloxetine Delayed-Release Capsules, USP, 40mg, and other strengths. Key considerations for alternative supplier qualification include their regulatory history, manufacturing site locations, capacity, and lead times for product delivery. Geographic diversity in sourcing is crucial to mitigate risks associated with regional regulatory issues or geopolitical events. Given the ongoing industry-wide scrutiny of nitrosamine impurities, any potential alternative supplier must demonstrate robust quality control systems, comprehensive impurity testing protocols, and a clear understanding of FDA's interim limits for N-nitroso compounds. The qualification process for a new API or finished drug product supplier can be lengthy, often spanning 12-24 months, encompassing audits, analytical testing, and stability studies. Therefore, immediate action is required to avoid prolonged supply disruptions and maintain patient access to this critical medication.
Broader Regulatory Context: Nitrosamine Impurities and Industry-Wide Scrutiny
While specific historical regulatory actions for Breckenridge Pharmaceutical, Inc. or Towa Pharmaceutical Europe, S.L. are not detailed in the available knowledge graph, this recall aligns with a broader industry trend of heightened FDA scrutiny on nitrosamine impurities in pharmaceutical products. The presence of N-nitroso-duloxetine above interim limits is not an isolated incident; similar issues have led to numerous recalls across various drug classes in recent years. For regulatory affairs heads, this underscores the need for continuous monitoring of FDA guidance on nitrosamines and proactive risk assessments across their entire product portfolio. The recent FDA Class II recall involving Essential Wellness Pharma's Progesterone Injection due to sterility assurance failures, occurring around the same time (June 2026), further illustrates the FDA's unwavering focus on CGMP compliance and product quality. This broader regulatory environment means that companies must invest significantly in analytical capabilities to detect and quantify these impurities, as well as in process improvements to prevent their formation. Business development executives should factor these stringent quality requirements into partnership evaluations and product development timelines, recognizing that compliance failures can lead to costly recalls, market withdrawals, and significant reputational damage.
Remediation Pathways and Future Regulatory Implications for Breckenridge
As a firm-initiated voluntary recall, Breckenridge Pharmaceutical, Inc. is responsible for executing the recall process, including notifying affected customers and managing returns. However, the underlying CGMP deviations at Towa Pharmaceutical Europe, S.L. will require a comprehensive remediation plan. This plan must address the root cause of the N-nitroso-duloxetine impurity formation and the systemic quality control failures that allowed it to exceed FDA interim limits. Regulatory affairs heads should anticipate a thorough FDA review of this remediation, potentially involving facility inspections at Towa Pharmaceutical Europe. Failure to adequately address these issues could lead to more severe regulatory actions, including an FDA Warning Letter to the manufacturing site, import alerts, or even further product withdrawals. For procurement directors, this implies potential long-term supply volatility from this specific manufacturing source. Companies sourcing from Towa Pharmaceutical Europe, S.L. should seek detailed assurances regarding the corrective and preventive actions (CAPAs) implemented. The timeline for full remediation and regaining FDA confidence can be extensive, often spanning several months to years, depending on the complexity of the issues and the responsiveness of the manufacturer. Proactive engagement with the FDA and transparent communication are critical for mitigating future regulatory risks and ensuring market access for essential medications like Duloxetine.